Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 19, 2010
Issued Date -
N/A
app pub date -
Dec 14, 2005
filing date -
Dec 15, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully